Drugs / NAGRESTIPEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01441115 | Sep 2011 → Apr 2013 | cancer, metastatic neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAGRESTIPEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108471 ↗ |
| Known as | BB-10010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108471 ↗ |
| Known as | BB-1001O | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108471 ↗ |
| Known as | ECI301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01441115 ↗ |
| Modality | Protein / enzyme biologic | “a 70 amino acid chemokine” NCT01441115 ↗ |
| Route | Intravenous | “ECI301 will be given in a vein during the second week of radiation therapy.” NCT01441115 ↗ |
| Target | CCR1 | “a ligand for C-C chemokine receptor type 1 (CCR1)” NCT01441115 ↗ |